More Company News

Hutchison China MediTech

Pricing of upsized US Public Secondary Offering of ADS
28 Jun 2019Read More

Hutchison China MediTech

Secondary Offering of ADS
28 Jun 2019Read More

Hutchison China MediTech

Surufatinib Phase III SANET-ep study meets primary endpoint at interim analysis and will stop early
14 Jun 2019Read More

Hutchison China MediTech

Results of EGM
29 May 2019Read More

Hutchison China MediTech

Application to list in Hong Kong and proposed global offering
15 Apr 2019Read More

Hutchison China MediTech

Initiation of Surufatinib China Phase IIb/III in Unresectable or Metastatic BTC
29 Mar 2019Read More

Hutchison China MediTech

Oral Presentations on Savolitinib Lung Cancer Programs at AACR
28 Mar 2019Read More

Hutchison China MediTech

2018 Annual Report and Notice of AGM
21 Mar 2019Read More

Hutchison China MediTech

2018 Final Results and Clinical Update
11 Mar 2019Read More

Hutchison China MediTech

Preliminary Phase II savolitinib/Imfinzi PRCC data at 2019 ASCO GU
12 Feb 2019Read More

1 2 3
Return to Hutchison China MediTech
© 2019 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).